Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.81 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.81 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.78 |
| ▸ | GAA | P10253 | 3/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | KIF11 | P52732 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6959316 | 0.83 | POLB (0.80) | SMN1; SMN2NPSR1L3MBTL1GAAMAPK1 | |
| SCHEMBL5351765 | 0.83 | KIF11 (0.77) | GAAMAPK1POLBHTTKIF11 | |
| SCHEMBL5339172 | 0.80 | KIF11 (0.65) | GAAMAPK1POLBHTTKIF11 | |
| SCHEMBL5345378 | 0.79 | MAPT (0.66) | GAAMAPK1POLBHTTKIF11 | |
| SCHEMBL3395556 | 0.79 | SMN1; SMN2 (0.80) | SMN1; SMN2NPSR1L3MBTL1GAAMAPK1 | |
| SCHEMBL13425955 | 0.79 | SMN1; SMN2 (0.80) | SMN1; SMN2NPSR1L3MBTL1GAAMAPK1 | |
| SCHEMBL3395549 | 0.79 | SMN1; SMN2 (0.80) | SMN1; SMN2NPSR1L3MBTL1GAAMAPK1 | |
| SCHEMBL3322690 | 0.79 | KDM4E (0.81) | NPSR1L3MBTL1GAALMNAPOLB | |
| SCHEMBL6340753 | 0.78 | PKM (0.77) | GAAKIF11KDM4EALDH1A1ADORA2B | |
| SCHEMBL10113219 | 0.77 | ALDH1A1 (0.78) | L3MBTL1GAAMAPK1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120100609-A1 | N-LINKED GLYCAN BIOSYNTHESIS MODULATORS | BIOMARIN PHARMACEUTICAL INC. | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120100609-A1 | N-LINKED GLYCAN BIOSYNTHESIS MODULATORS | ENGASE, GALNT1, GALNT13 | SMN1; SMN2 4780/4885NPSR1 2181/4885L3MBTL1 1767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.